|
|
| | aderbasib Basic information |
| Product Name: | aderbasib | | Synonyms: | (6S,7S)-Methyl 7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-car;aderbasib;(6S,7S)-7-[(Hydroxyamino)carbonyl]-6-[(4-phenyl-1-piperazinyl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylic acid methyl ester;Incb7839;Unii-V9yl6nej3g;INCB 007839;(6S,7S)-Methyl 7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-;(6S,7S)-Methyl 7-(hydroxycarbaMoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate | | CAS: | 791828-58-5 | | MF: | C21H28N4O5 | | MW: | 416.47 | | EINECS: | | | Product Categories: | Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Amines;Aromatics;Chiral Reagents | | Mol File: | 791828-58-5.mol |  |
| | aderbasib Chemical Properties |
| density | 1.38 | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (240.11 mM; Need ultrasonic) | | pka | 9.33±0.23(Predicted) | | form | Solid | | color | White to light yellow |
| | aderbasib Usage And Synthesis |
| Uses | Aderbasib is a azaspiro[2.5]octanehydroxamide derivative as inhibitor of metalloproteases for the treatment of disorders such as cancer, arthritis, cardiovascular or skin disorders. | | in vivo | Aderbasib (intraperitoneal injection; 50 mg/kg; 5 days per week beginning four weeks; 2 weeks) blocks glioma growth of SU-pcGBM2 NSG mice xenografts[1].INCB7839 can be formulated in 2% DMSO, 2% Tween 80, 48% PEG300, 48% water as a injection solution. This is for literature reference only[1]. | Animal Model: | NSG mice[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; 50 mg/kg; 5 days per week beginning four weeks; 2 weeks | | Result: | Robustly inhibited growth of pediatric glioblastoma orthotopic xenografts. |
| | IC 50 | ADAM10; ADAM17 |
| | aderbasib Preparation Products And Raw materials |
|